MedWatch

Biotech Chairman: You pay for the network

Could international board members be the way to success for unlisted, Danish biotech companies? That depends on a number of things, says Martin Bonde, Chairman in the industry organization Dansk Biotek.

What do the unlisted, Danish biotech companies Santaris Pharma, Ascendis Pharma, EpiTherapeutics, Forward Pharma, and Symphogen all have in common, aside from being among the most promising biotech companies in the country?

The answer is a high level of internationalization in their board rooms. The question is if more Danish biotech companies could go further, if they brought international board members on board, as it were, preferably early on in their development.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier